

Stella Stergiopoulos

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/893918/stella-stergiopoulos-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

19
papers

192
citations

9
h-index

13
g-index

21
ext. papers

242
ext. citations

2.3
avg, IF

3.26
L-index

#	Paper	IF	Citations
19	Shingles vaccination uptake in Massachusetts adults aged 50 years and older. <i>Vaccine</i> , 2021 , 39, 6781-6786	1.1	0
18	Measuring the Impact of Patient Engagement and Patient Centricity in Clinical Research and Development. <i>Therapeutic Innovation and Regulatory Science</i> , 2020 , 54, 103-116	1.2	17
17	Assessing Patient Participation Burden Based on Protocol Design Characteristics. <i>Therapeutic Innovation and Regulatory Science</i> , 2020 , 54, 598-604	1.2	1
16	Assessing Patient Participation Burden Based on Protocol Design Characteristics. <i>Therapeutic Innovation and Regulatory Science</i> , 2019 , 2168479019867284	1.2	5
15	Measuring the Impact of Patient Engagement and Patient Centricity in Clinical Research and Development. <i>Therapeutic Innovation and Regulatory Science</i> , 2019 , 216847901881751	1.2	9
14	Evaluating the Completeness of ClinicalTrials.gov. <i>Therapeutic Innovation and Regulatory Science</i> , 2019 , 53, 307-317	1.2	11
13	Adverse Drug Reaction Case Safety Practices in Large Biopharmaceutical Organizations from 2007 to 2017: An Industry Survey. <i>Pharmaceutical Medicine</i> , 2019 , 33, 499-510	2.3	7
12	Cost Drivers of a Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Phase 3 Clinical Trial. <i>Clinical Infectious Diseases</i> , 2018 , 66, 72-80	11.6	11
11	Baseline Assessment of a Global Clinical Investigator Landscape Poised for Structural Change. <i>Therapeutic Innovation and Regulatory Science</i> , 2017 , 51, 575-581	1.2	4
10	Mobile Nurse Services in Clinical Trials: Usage and Industry Perceptions. <i>Therapeutic Innovation and Regulatory Science</i> , 2016 , 50, 442-449	1.2	3
9	The Impact of Protocol Amendments on Clinical Trial Performance and Cost. <i>Therapeutic Innovation and Regulatory Science</i> , 2016 , 50, 436-441	1.2	25
8	A Survey of Adverse Event Reporting Practices Among US Healthcare Professionals. <i>Drug Safety</i> , 2016 , 39, 1117-1127	5.1	25
7	Evaluating AE Reporting of Two Off-Patent Biologics to Inform Future Biosimilar Naming and Reporting Practices. <i>Drug Safety</i> , 2015 , 38, 687-92	5.1	2
6	Regulatory Definitions and Good Pharmacovigilance Practices in Social Media: Challenges and Recommendations. <i>Therapeutic Innovation and Regulatory Science</i> , 2015 , 49, 840-851	1.2	8
5	Quantifying the magnitude and cost of collecting extraneous protocol data. <i>American Journal of Therapeutics</i> , 2015 , 22, 117-24	1	19
4	Identifying and Quantifying the Accuracy of Product Name Attribution of US-Sourced Adverse Event Reports in MedWatch of Somatotropins and Insulins. <i>Therapeutic Innovation and Regulatory Science</i> , 2015 , 49, 706-716	1.2	5
3	Evaluating the completeness and accuracy of MedWatch data. <i>American Journal of Therapeutics</i> , 2014 , 21, 442-6	1	27

2	New Governance Mechanisms to Optimize Protocol Design. <i>Therapeutic Innovation and Regulatory Science</i> , 2013 , 47, 651-655	1.2	9
1	Mapping and Characterizing the Development Pathway from Non-Clinical through Early Clinical Drug Development. <i>Pharmaceutical Medicine</i> , 2012 , 26, 297-307	2.3	1